Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency

STOCKHOLM, SWEDEN, Sept. 28 2026. (GLOBE NEWSWIRE) — Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX) today announced that the U.S. Food and Drug Administration (FDA) has approved EMCITATE® (tiratricol), a thyroid hormone receptor agonist, for the treatment of peri…